[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
1. Aparajita R, Gomez D, Verbeke CS, Menon KV: Papillary adenoma of the distal common bile duct associated with a synchronous carcinoma of the peri-ampullary duodenum. JOP; 2008;9(2):212-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenoma of the distal common bile duct associated with a synchronous carcinoma of the peri-ampullary duodenum.
  • CONTEXT: Benign tumours of the biliary tract are an extremely rare group of neoplasms.
  • Coincidence of a biliary adenoma of the distal common bile duct and a synchronous adenocarcinoma of the peri-ampullary duodenum has never been reported in the literature.
  • CASE REPORT: We report a case of a papillary adenoma in the common bile duct in a 75-year-old female, who had synchronous invasive adenocarcinoma of the peri-ampullary duodenum.
  • CONCLUSION: Isolated papillary adenoma of the bile duct is extremely rare, and in this unusual case it coincided with a peri-ampullary duodenal adenocarcinoma.
  • However, this is a rare instance of an incidental finding within the distal bile duct following pancreaticoduodenectomy for curative treatment of a peri-ampullary adenocarcinoma.
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Common Bile Duct / pathology. Common Bile Duct Neoplasms / pathology. Duodenal Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18326932.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


2. Lee TS, Kim HK, Ahn HM, Lee UJ, Choi YC, John BM, Park TI, Koo JH: [A case of early bile duct cancer arising from villous adenoma in choledochal cyst]. Korean J Gastroenterol; 2009 Jul;54(1):55-9
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of early bile duct cancer arising from villous adenoma in choledochal cyst].
  • Herein, we report a rare case of bile duct adenoma arising from choledochal cyst with anomalous union of pancreaticobiliary duct (AUPBD).
  • She had received common bile duct (CBD) exploration and choledocholithotomy and cholecystectomy 3 months earlier under the diagnosis of multiple CBD stones.
  • On magnetic resonance cholangiopancreatography, the filling defect was confirmed as 2 cm polypoid mass attached to the distal bile duct wall.
  • On histological examination, adenoma with focal carcinoma change arising from choledochal cyst was diagnosed.
  • [MeSH-major] Adenoma, Villous / diagnosis. Bile Duct Neoplasms / diagnosis. Choledochal Cyst / diagnostic imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696552.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


3. Kim YS, Rha SE, Oh SN, Jung SE, Shin YR, Choi BG, Byun JY, Jung ES, Kim DG: Imaging findings of intrahepatic bile duct adenoma (peribiliary gland hamartoma): a case report and literature review. Korean J Radiol; 2010 Sep-Oct;11(5):560-5
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for intrahepatic bile duct adenoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging findings of intrahepatic bile duct adenoma (peribiliary gland hamartoma): a case report and literature review.
  • Intrahepatic bile duct adenoma is a rare benign epithelial hepatic tumor derived from bile duct cells.
  • We report the imaging findings of a patient with bile duct adenoma, which appeared as a small heterogeneously enhancing mass with focal small cystic change on CT and MRI.
  • Although rare, bile duct adenoma should be considered as a differential diagnosis of a small hypervascular tumor located in the periphery of liver.
  • [MeSH-major] Adenoma, Bile Duct / diagnosis. Bile Duct Neoplasms / diagnosis. Hamartoma / diagnosis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for bile duct adenoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ulster Med J. 1999 Nov;68(2):114-5 [10661642.001]
  • [Cites] Am Surg. 1975 Feb;41(2):106-8 [1122059.001]
  • [Cites] Arch Surg. 1978 Mar;113(3):272-4 [205188.001]
  • [Cites] Arch Pathol Lab Med. 1984 Nov;108(11):922-4 [6548370.001]
  • [Cites] Am J Surg Pathol. 1988 Sep;12(9):708-15 [3046396.001]
  • [Cites] Radiographics. 2009 Oct;29(6):1725-48 [19959518.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):858-64 [8669534.001]
  • [Cites] J Magn Reson Imaging. 1999 Aug;10(2):196-201 [10441025.001]
  • [Cites] J Comput Assist Tomogr. 1999 Sep-Oct;23(5):690-5 [10524847.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):381-9 [15725808.001]
  • [Cites] Radiat Med. 2006 Jul;24(6):459-62 [16958429.001]
  • [Cites] J Comput Assist Tomogr. 1993 May-Jun;17(3):397-402 [8388005.001]
  • (PMID = 20808701.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ PMC2930166
  • [Keywords] NOTNLM ; Adenoma / Bile duct / Computed tomography (CT) / Liver / Magnetic resonance (MR)
  •  go-up   go-down


Advertisement
4. Maeda E, Uozumi K, Kato N, Akahane M, Inoh S, Inoue Y, Beck Y, Goto A, Makuuchi M, Ohtomo K: Magnetic resonance findings of bile duct adenoma with calcification. Radiat Med; 2006 Jul;24(6):459-62
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance findings of bile duct adenoma with calcification.
  • Computed tomographic (CT) and magnetic resonance (MR) appearances of bile duct adenoma (BDA in a patient who underwent partial hepatectomy of segment 8 are presented.
  • [MeSH-major] Adenoma, Bile Duct / diagnosis. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic / pathology. Calcinosis / diagnosis. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16958429.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Mosnier JF, Kandel C, Cazals-Hatem D, Bou-Hanna C, Gournay J, Jarry A, Laboisse CL: N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas. Mod Pathol; 2009 Feb;22(2):182-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a definite immunoprofile of this tumor is missing, the histopathologic diagnosis of intrahepatic cholangiocarcinoma is difficult.
  • The aim of this study was to explore E- and N-cadherin expressions in intrahepatic bile duct tumors, and to determine their potential interest in differential diagnosis.
  • Normal liver tissue, 5 cirrhosis with ductular reaction, 5 focal nodular hyperplasia, 5 bile duct hamartomas, 5 bile duct adenomas, and 45 intrahepatic cholangiocarcinomas from Caucasian patients were studied.
  • In normal liver, epithelial cells of intrahepatic bile ducts, whatever their caliber, as well as hepatocytes, coexpressed E- and N-cadherins at their plasma membranes.
  • All the benign lesions and 30 of the 45 intrahepatic cholangiocarcinomas (23/29 peripheral and 7/16 hilar) also expressed N-cadherin.
  • [MeSH-major] Antigens, CD / analysis. Bile Duct Neoplasms / immunology. Bile Ducts, Intrahepatic / immunology. Biomarkers, Tumor / analysis. Cadherins / analysis. Cholangiocarcinoma / immunology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622386.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CDH1 protein, human; 0 / CDH2 protein, human; 0 / Cadherins; 0 / KRT7 protein, human; 0 / Keratin-7
  •  go-up   go-down


6. National Toxicology Program: NTP technical report on the toxicology and carcinogenesis studies of 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) (CAS No. 35065-27-1) in female Harlan Sprague-Dawley rats (Gavage studies). Natl Toxicol Program Tech Rep Ser; 2006 May;(529):4-168
Hazardous Substances Data Bank. 2,2',4,4',5,5'-HEXACHLOROBIPHENYL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since human exposure to DLCs always involves a complex mixture, the toxic equivalency factor (TEF) methodology has been developed as a mathematical tool to assess the health risk posed by complex mixtures of these compounds.
  • The TEF methodology is a relative potency scheme that ranks the dioxin-like activity of a compound relative to TCDD, which is the most potent congener.
  • This allows for the estimation of the potential dioxin-like activity of a mixture of chemicals based on a common mechanism of action involving an initial binding of DLCs to the AhR.
  • 2,2',4,4',5,5'-Hexachlorobiphenyl (PCB 153) was produced as a component of some commercial PCB mixtures before 1977 for the electric industry as a dielectric insulating fluid for transformers and capacitors.
  • PCB 153 was selected for study by the National Toxicology Program as a part of the dioxin TEF evaluation to assess the cancer risk posed by complex mixtures of polychlorinated dibenzodioxins (PCDDs), polychlorinated dibenzofurans (PCDFs), and polychlorinated biphenyls (PCBs).
  • The incidences of diffuse fatty change in the 300 microg/kg or greater groups and bile duct hyperplasia of the liver in 300 microg/kg and 3,000 microg/kg (core and stop-exposure) groups were significantly increased.
  • At 2 years, two cholangiomas were seen in the 1,000 microg/kg group and two cholangiomas were seen in the 3,000 microg/kg stop-exposure group.
  • A single hepatocellular adenoma was observed in the 3,000 microg/kg core study group.
  • CONCLUSIONS: Under the conditions of this 2-year gavage study there was equivocal evidence of carcinogenic activity of PCB 153 in female Harlan Sprague-Dawley rats based on the occurrences of cholangioma of the liver.
  • [MeSH-major] Bile Ducts, Intrahepatic / pathology. Carcinogens / toxicity. Polychlorinated Biphenyls / toxicity
  • [MeSH-minor] Adenoma, Bile Duct / chemically induced. Adenoma, Bile Duct / pathology. Administration, Oral. Animals. Bile Duct Neoplasms / chemically induced. Bile Duct Neoplasms / pathology. Cell Enlargement / drug effects. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Female. Hepatocytes / drug effects. Hepatocytes / pathology. Liver / drug effects. Liver / pathology. Organ Size / drug effects. Rats. Rats, Sprague-Dawley. Thyroid Hormones / blood. Toxicity Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835634.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Thyroid Hormones; DFC2HB4I0K / Polychlorinated Biphenyls; ZRU0C9E32O / 2,4,5,2',4',5'-hexachlorobiphenyl
  •  go-up   go-down


7. Khan SA, Toledano MB, Taylor-Robinson SD: Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford); 2008;10(2):77-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cholangiocarcinoma (CCA) is a fatal cancer of the biliary epithelium, arising either within the liver (intrahepatic, ICC) or in the extrahepatic bile ducts (extrahepatic ECC).
  • These include primary sclerosing cholangitis, liver fluke infestation, congenital fibropolycystic liver, bile duct adenomas, and biliary papillomatosis, hepatolithiasis, chemical carcinogens such as nitrosamines, Thorotrast, chronic viral hepatitis, cirrhosis, chronic non-alcoholic liver disease and obesity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Gastroenterol Hepatol. 2007 Oct;5(10):1221-8 [17689296.001]
  • [Cites] J Hepatol. 2002 Dec;37(6):806-13 [12445422.001]
  • [Cites] Am J Gastroenterol. 2007 May;102(5):1016-21 [17324130.001]
  • [Cites] J Hepatol. 2006 Dec;45(6):856-67 [17030071.001]
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):638-41 [17109384.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):873-5 [16788161.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1198-203 [16775181.001]
  • [Cites] BMC Cancer. 2002 May 3;2:10 [11991810.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1049-55 [12201863.001]
  • [Cites] Br J Surg. 2002 Aug;89(8):962-70 [12153620.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):959-64 [11808716.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1353-7 [11391522.001]
  • [Cites] Gut. 2001 Jun;48(6):816-20 [11358902.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2471-7 [10861422.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Dec;14(12):1144-9 [10634149.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1751-8 [16736026.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):620-6 [15765398.001]
  • [Cites] Hepatology. 1998 Oct;28(4):921-5 [9755226.001]
  • [Cites] Int J Epidemiol. 1996 Oct;25(5):933-40 [8921477.001]
  • [Cites] World J Surg. 1995 Jul-Aug;19(4):637-41 [7676713.001]
  • [Cites] Br J Cancer. 1984 Sep;50(3):389-97 [6087869.001]
  • [Cites] Cancer Res. 1978 Dec;38(12):4634-9 [214229.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):127-37 [15192786.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):115-25 [15192785.001]
  • [Cites] J Hepatol. 2004 Mar;40(3):472-7 [15123362.001]
  • [Cites] Gut. 2003 Apr;52(4):586-91 [12631674.001]
  • [Cites] Abdom Imaging. 2003 Jan-Feb;28(1):72-4 [12483389.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 6;99(11):895-7 [17551150.001]
  • (PMID = 18773060.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2504381
  • [Keywords] NOTNLM ; Cholangiocarcinoma
  •  go-up   go-down


8. Takahashi S, Takada K, Kawano Y, Miyanishi K, Ishiwatari H, Hayashi T, Sagawa T, Sato T, Sato Y, Takimoto R, Kobune M, Kuroiwa G, Hirayama M, Tobioka H, Hirata K, Omatsu M, Hasegawa T, Kato J: [Cholangiocarcinoma with bile duct adenoma and hamartoma-like lesion in the bile duct]. Nihon Shokakibyo Gakkai Zasshi; 2010 Mar;107(3):461-9
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cholangiocarcinoma with bile duct adenoma and hamartoma-like lesion in the bile duct].
  • This showed a number of bile ductules with variable amounts of stroma, well circumscribed but not encapsulated, so the lesion was diagnosed as a cholangiocarcinoma.
  • In addition, cystically dilated ductules resembling bile duct hamartoma and bile duct adenoma adjacent to the tumor were found, but with no area of transition among them.
  • In the Glisson's capsule around the tumor, there was also a bile duct hamartoma.
  • [MeSH-major] Adenoma / pathology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / pathology. Hamartoma / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20203450.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Hughes NR, Goodman ZD, Bhathal PS: An immunohistochemical profile of the so-called bile duct adenoma: clues to pathogenesis. Am J Surg Pathol; 2010 Sep;34(9):1312-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An immunohistochemical profile of the so-called bile duct adenoma: clues to pathogenesis.
  • The so-called bile duct adenoma and peribiliary glands are characterized by the expression of two foregut antigens (designated D10 and 1F6) and secretion of acid mucin.
  • On account of this similarity in phenotype and their frequent close association with a large caliber bile duct, it was earlier suggested that bile duct adenoma represent a peribiliary gland hamartoma.
  • Here, we compare the expression of 13 tissue antigens in bile duct adenomas, other benign bile duct lesions, and various foregut-derived tissues, to further investigate the bile duct adenoma phenotype and pathogenesis.
  • Five foregut antigens (D10, 1F6, MUC6, MUC5AC, and TFF2) and secretion of acid mucin were of use in distinguishing bile duct adenoma from other hepatic lesions.
  • 1F6 and MUC6 were normally present in bile ductules and canals of Hering, whereas the epithelium lining the larger bile ducts stained focally for D10, MUC5AC, MUC6, or TFF2 in, respectively, 21%, 36%, 43%, and 100% of the livers examined.
  • Thirty-six bile duct adenomas examined were distinguished by expression of MUC6 (94% of bile duct adenoma), MUC5AC (90%), TFF2 (80%), D10 (67%), and 1F6 (61%), and varying degrees of acid mucin secretion (100%).
  • Of 30 bile duct adenoma tested for all 5 antigens, 40% expressed all 5, 27% expressed 4, 17% expressed 3, 13% expressed 2, and 1 expressed only MUC6.
  • The distinguishing feature of so-called bile duct adenoma is their display of the same phenotype as pyloric gland metaplasia.
  • It is concluded that they develop as a localized biliary healing response equivalent to the function of a peribiliary gland or pyloric gland metaplasia in the foregut.
  • [MeSH-major] Adenoma, Bile Duct / pathology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20679879.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


10. Ignee A, Piscaglia F, Ott M, Salvatore V, Dietrich CF: A benign tumour of the liver mimicking malignant liver disease--cholangiocellular adenoma. Scand J Gastroenterol; 2009;44(5):633-6
Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A benign tumour of the liver mimicking malignant liver disease--cholangiocellular adenoma.
  • OBJECTIVE: To describe three patients with liver lesions mimicking malignant tumours diagnosed finally, using contrast-enhanced ultrasound, as cholangiocellular adenoma (bile duct adenoma).
  • Pathological analysis (including the reference pathology) revealed cholangiocellular adenoma in all of them.
  • CONCLUSION: Cholangiocellular adenoma is a rare entity and can be a reason for possible false malignant diagnosis using contrast-enhanced ultrasound.
  • [MeSH-major] Adenoma, Bile Duct / pathology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Liver Neoplasms / pathology

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19396663.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


11. Sotona O, Cecka F, Neoral C, Ferko A, Rejchrt S, Podhola M, Subrt Z, Jon B: Papillary adenoma of the extrahepatic biliary tract--a rare cause of obstructive jaundice. Acta Gastroenterol Belg; 2010 Apr-Jun;73(2):270-3
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenoma of the extrahepatic biliary tract--a rare cause of obstructive jaundice.
  • The authors present a case of papillary adenoma of the extrahepatic biliary tract presenting as obstructive jaundice.
  • The patient was treated by bile duct resection with Roux-en-Y hepaticojejunostomy.
  • Adenoma of the bile duct is a rare entity.
  • [MeSH-major] Adenoma / complications. Bile Duct Neoplasms / complications. Bile Ducts, Extrahepatic. Jaundice, Obstructive / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20690568.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


12. Hornick JL, Lauwers GY, Odze RD: Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol; 2005 Mar;29(3):381-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver.
  • Not uncommonly, bile duct adenomas (BDAs) and hamartomas (BDHs) of the liver may be difficult to distinguish from metastatic well-differentiated ductal adenocarcinoma of the pancreas.
  • The slides were evaluated in a blinded fashion, and the results were compared between the benign and malignant lesions.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma / pathology. Bile Duct Neoplasms / pathology. Hamartoma / pathology. Liver Diseases / pathology. Pancreatic Neoplasms / pathology


13. Evert M, Schildhaus HU, Schneider-Stock R, Dombrowski F: Cystic cholangiomas after transplantation of pancreatic islets into the livers of diabetic rats. Virchows Arch; 2006 Jun;448(6):776-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic cholangiomas after transplantation of pancreatic islets into the livers of diabetic rats.
  • Islet transplantation is increasingly used as a therapy for human type 1 diabetes mellitus.
  • In our study, we investigated the effect of the transplantation of a low number (n = 350) of pancreatic islets into the right liver part on the neighboring portal bile ducts.
  • During the next 12-24 months, many peri-insular ductules progressed via tumor-like cystic lesions to large cystic cholangiomas, accompanied by a translocation of the insulin receptor into the cytoplasm and an increase in expression of insulin-related signaling proteins (Insulin-receptor-substrate-1, Raf-1, Mek-1).
  • After 24 months, 53% of rats with low-number transplantation exhibited at least one cholangioma >10 mm, significantly outnumbering tumor development in the transplant-free left liver part and in any control group.
  • Conclusively, low-number intrahepatic islet transplantation, most likely acting by permanent local hyperinsulinism, leads to prolonged cholangiocellular proliferation in streptozotocin- and in autoimmune-diabetic rats, resulting in the development of benign cystic cholangiomas.
  • [MeSH-major] Adenoma, Bile Duct / etiology. Bile Duct Neoplasms / etiology. Bile Ducts, Intrahepatic / pathology. Diabetes Mellitus, Experimental / complications. Diabetes Mellitus, Type 1 / complications. Islets of Langerhans Transplantation / adverse effects


14. Jakab C, Kiss A, Schaff Z, Szabó Z, Rusvai M, Gálfi P, Szabára A, Sterczer A, Kulka J: Claudin-7 protein differentiates canine cholangiocarcinoma from hepatocellular carcinoma. Histol Histopathol; 2010 07;25(7):857-64
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: Necropsy samples included 15 canine normal liver tissue samples, 10 hepatocellular nodular hyperplasias, 6 hepatocellular adenomas, 15 well-differentiated and 6 poorly differentiated hepatocellular carcinomas, 6 cholangiocellular hyperplasias, 10 cholangiocellular adenomas, 15 well-differentiated and 6 poorly differentiated cholangiocarcinomas, 6 normal extrahepatic bile ducts, 8 normal gall bladder tissue samples, and 5 cystic mucinous hyperplasias of the gall bladder.
  • In all cholangiocellular hyperplasia samples and in all cholangiocellular adenoma samples the benign cholangiocytes showed intense basolateral membrane positivity for claudin-7.
  • Neither the hyperplastic nodules of the liver cells nor the hepatocellular adenomas reacted with claudin-7.
  • The epithelial cells of canine normal extrahepatic bile ducts, gall bladder and cystic mucinous hyperplasias of the gall bladder showed intense basolateral membrane positivity for claudin-7.
  • CONCLUSION: Consequently, we hypothesize that claudin-7 is an excellent immunohistochemical marker of the cholangiocellular differentiation in canines and can be used to detect benign and malignant proliferative lesions of the canine biliary tract.
  • [MeSH-minor] Adenoma, Liver Cell / metabolism. Adenoma, Liver Cell / pathology. Animals. Biliary Tract / metabolism. Biliary Tract / pathology. Case-Control Studies. Cholangiocarcinoma / metabolism. Cholangiocarcinoma / pathology. Claudins. Dogs. Epithelial Cells / metabolism. Epithelial Cells / pathology. Liver / metabolism. Liver / pathology. Neoplasms / metabolism. Neoplasms / pathology. Proteins / metabolism. Tight Junctions / metabolism. Tight Junctions / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20503174.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Claudins; 0 / Proteins
  •  go-up   go-down


15. Gambarotti M, Medicina D, Baronchelli C, Bercich L, Bonetti F, Facchetti F: Alpha-1-antitrypsin-positive "signet-ring" bile duct adenoma in a patient with M(MALTON) mutation. Int J Surg Pathol; 2008 Apr;16(2):218-21
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-1-antitrypsin-positive "signet-ring" bile duct adenoma in a patient with M(MALTON) mutation.
  • The nodule showed the histological features of a bile duct adenoma.
  • The selective recurrence of large alpha-1-antitrypsin globules within the bile ducts may indicate a neoplastic rather than a reactive or hamartomatous nature of the nodule.
  • [MeSH-major] Adenoma / genetics. Bile Duct Neoplasms / genetics. Bile Ducts, Intrahepatic. Mutation. alpha 1-Antitrypsin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417685.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha 1-Antitrypsin
  •  go-up   go-down


16. Kunisaki SM, Hertl M, Bodner BE, Cosimi AB: Mirizzi syndrome secondary to an adenoma of the cystic duct. J Hepatobiliary Pancreat Surg; 2005;12(2):159-62
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mirizzi syndrome secondary to an adenoma of the cystic duct.
  • Bile duct adenomas are uncommon lesions that can cause obstructive jaundice.
  • We report the unusual case of a 54-year-old man who developed Mirizzi syndrome secondary to a bile duct papillary adenoma located in the cystic duct remnant.
  • A case report is presented, together with a review of extrahepatic bile duct adenomas published in the English-language literature, with special attention directed toward the clinical manifestations, locations, and prognosis of these tumors.
  • Bile duct adenomas are very rare tumors.
  • Most lesions were located in the distal common bile duct or at the ampulla of Vater.
  • There were no previous case reports of extrinsic common bile duct obstruction caused by tumors within the cystic duct.
  • We describe here a very rare, acalculous variant of Mirizzi syndrome secondary to a solitary papillary adenoma of the cystic duct.
  • In general, bile duct adenomas are uncommon lesions that are difficult to diagnoses preoperatively.
  • [MeSH-major] Adenoma / complications. Bile Duct Neoplasms / complications. Cholestasis / etiology. Cystic Duct

  • Genetic Alliance. consumer health - Mirizzi syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868083.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 28
  •  go-up   go-down


17. Morris-Stiff GJ, Senda Y, Verbeke CS, Lodge PA: Papillary adenoma arising in the left hepatic duct: an unusual tumour in an uncommon location. Eur J Gastroenterol Hepatol; 2010 Jul;22(7):886-8
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for papillary adenoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenoma arising in the left hepatic duct: an unusual tumour in an uncommon location.
  • Bile duct adenomas are rare tumours that arise more frequently in the distal extrahepatic biliary tree.
  • We report the case of a papillary adenoma arising at the junction of the common and left hepatic ducts and review the available literature on this rare entity.
  • Histological evaluation of the resected specimen confirmed a papillary adenoma with mild dysplasia.
  • [MeSH-major] Adenoma / diagnosis. Adenoma, Bile Duct / diagnosis. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20545030.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.3.2.2 / gamma-Glutamyltransferase
  • [Number-of-references] 10
  •  go-up   go-down


18. Alvaro D, Cannizzaro R, Labianca R, Valvo F, Farinati F, Italian Society of Gastroenterology (SIGE), Italian Association of Hospital Gastroenterology (AIGO), Italian Association of Medical Oncology (AIOM), Italian Association of Oncological Radiotherapy (AIRO): Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO). Dig Liver Dis; 2010 Dec;42(12):831-8
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of Cholangiocellular carcinoma (CCA) is increasing, due to a sharp increase of the intra-hepatic form.
  • Evidence-ascertained risk factors for CCA are primary sclerosing cholangitis, Opistorchis viverrini infection, Caroli disease, congenital choledocal cist, Vater ampulla adenoma, bile duct adenoma and intra-hepatic lithiasis.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20702152.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] Netherlands
  • [Investigator] Avuzzi B; Buscarini E; Fornasarig M; Iacono C; Maiero S; Mosconi S; Muto P; Tasca C; Vanin V
  •  go-up   go-down


19. Gütgemann I, Haas S, Berg JP, Zhou H, Büttner R, Fischer HP: CD56 expression aids in the differential diagnosis of cholangiocarcinomas and benign cholangiocellular lesions. Virchows Arch; 2006 Apr;448(4):407-11
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD56 expression aids in the differential diagnosis of cholangiocarcinomas and benign cholangiocellular lesions.
  • CD56 (neuronal cell adhesion molecule, N-CAM) has been reported in neuroendocrine tumours and as a marker of reactive biliary epithelial cells.
  • Reactive bile ductules adjacent to cirrhotic nodules as well as in focal nodular hyperplasia were CD56 positive.
  • Twelve of 17 (70.5%) bile duct adenomas were CD56 positive, whereas von Meyenburg complexes expressed CD56 only very focally in less than 5% of lesional cells.
  • Bile duct cysts were negative for CD56 with the exception of focally interspersed neuroendocrine cells, similar to that seen in segmental bile ducts.
  • [MeSH-major] Antigens, CD56 / metabolism. Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic / metabolism. Biomarkers, Tumor / metabolism. Cholangiocarcinoma / metabolism. Cholangitis / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenoma, Bile Duct / diagnosis. Adenoma, Bile Duct / metabolism. Bile Ducts, Extrahepatic / metabolism. Bile Ducts, Extrahepatic / pathology. Choledochal Cyst / diagnosis. Choledochal Cyst / metabolism. Cystadenoma, Mucinous / diagnosis. Cystadenoma, Mucinous / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Liver Cirrhosis / diagnosis. Liver Cirrhosis / metabolism

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16411132.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Haas S, Gütgemann I, Wolff M, Fischer HP: Intrahepatic clear cell cholangiocarcinoma: immunohistochemical aspects in a very rare type of cholangiocarcinoma. Am J Surg Pathol; 2007 Jun;31(6):902-6
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clear cell cholangiocarcinoma is a very unusual variant of peripheral bile duct carcinoma.
  • Positive expression of CK7 indicated a cholangiocellular origin.
  • Electronmicroscopy revealed only a few glycogen granula, but numerous cytoplasmic lipoid vacuoles as a possible explanation for the clear cell phenotype.
  • They also show CD56 expression which is a very uncommon finding for intrahepatic cholangiocarcinomas.
  • As CD56 expression is also found in reactive bile ducts and bile duct adenomas, one may speculate that these rare neoplasms may originate from reactive bile ducts or cholangiomatous lesions.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / pathology

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527078.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Keratin-7
  •  go-up   go-down


21. Sohn VY, Arthurs ZM, Martin MJ, Sebesta JA, Branch JB, Champeaux AL: Incidental pathologic findings in open resectional gastric bypass specimens with routine cholecystectomy and appendectomy. Surg Obes Relat Dis; 2008 Sep-Oct;4(5):608-11
MedlinePlus Health Information. consumer health - Stomach Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This procedure allows for pathologic assessment of otherwise normal viscera routinely removed as a part of the gastric bypass.
  • In the gallbladder the sole abnormality, other than cholelithiasis, was an adenomyoma.
  • Other resected findings included five Meckel's diverticula, one bile duct adenoma, and one sigmoid diverticulum.

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586563.001).
  • [ISSN] 1550-7289
  • [Journal-full-title] Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
  • [ISO-abbreviation] Surg Obes Relat Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Munshi AG, Hassan MA: Common bile duct adenoma: case report and brief review of literature. Surg Laparosc Endosc Percutan Tech; 2010 Dec;20(6):e193-4
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for bile duct adenoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common bile duct adenoma: case report and brief review of literature.
  • Papillary adenomas of the common bile duct are a rare entity with few published case reports and limited knowledge on its natural progression.
  • We report here a case of common bile duct papillary adenoma in a 69-year-old female who presented with symptoms of common bile duct obstruction.
  • She was treated with local endoscopic excision of the mass that has benign features.
  • A brief review of literature is discussed with a proposed treatment plan for follow-up with surveillance endoscopy and ultrasonography as opposed to the radical resection for benign findings on pathology.
  • [MeSH-major] Adenoma / surgery. Common Bile Duct Neoplasms / surgery
  • [MeSH-minor] Aged. Cholangiopancreatography, Endoscopic Retrograde. Common Bile Duct / pathology. Common Bile Duct Diseases / diagnosis. Dilatation, Pathologic. Female. Humans. Sphincterotomy, Endoscopic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21150400.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


23. Yamazaki S, Takayama T, Watanabe Y, Oikawa T, Hayashi Y, Kochi M, Moriguchi M, Higaki T, Inoue K: Imaging modality of three-dimensional CT in caudate cholangioma: assessment for resectability. Hepatogastroenterology; 2007 Mar;54(74):397-9
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging modality of three-dimensional CT in caudate cholangioma: assessment for resectability.
  • Conventional preoperative imaging has limited modality and accuracy in primary intrahepatic cholangiocellular carcinoma (ICC) in the caudate lobe (CL).
  • His lesion was judged unresectable hilar cholangiocellular carcinoma because it had spread widely to the bilateral lobe of the liver as shown by preoperative imaging studies.
  • The left lobe showed marked atrophy and intrahepatic biliary duct (IHBD) dilatation of the whole liver was observed.
  • [MeSH-major] Bile Duct Neoplasms / radiography. Bile Ducts, Intrahepatic / radiography. Cholangiocarcinoma / radiography. Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Tomography, Spiral Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523283.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


24. Kobuke T, Tazuma S, Hyogo H, Chayama K: A Ligand for peroxisome proliferator-activated receptor gamma inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma. Dig Dis Sci; 2006 Sep;51(9):1650-7
Hazardous Substances Data Bank. PIOGLITAZONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Ligand for peroxisome proliferator-activated receptor gamma inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma.
  • PPAR( expression in HuH-28 and HuCCT1 cells (intrahepatic bile duct carcinoma) was determined using the reverse transcription-polymerase chain reaction (RT-PCR).
  • [MeSH-minor] Bile Duct Neoplasms / enzymology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / enzymology. Bile Ducts, Intrahepatic / pathology. Caspase 3. Caspase 9. Caspases / metabolism. Cell Culture Techniques. Cell Line, Tumor. Cell Proliferation / drug effects. Humans. Ligands. Molecular Biology. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16927143.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chromans; 0 / Ligands; 0 / PPAR gamma; 0 / RNA, Neoplasm; 0 / Thiazolidinediones; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP9 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9; EC 3.4.22.- / Caspases; I66ZZ0ZN0E / troglitazone; X4OV71U42S / pioglitazone
  •  go-up   go-down


25. Katsinelos P, Basdanis G, Chatzimavroudis G, Karagiannoulou G, Katsinelos T, Paroutoglou G, Papaziogas B, Paraskevas G: Pancreatitis complicating mucin-hypersecreting common bile duct adenoma. World J Gastroenterol; 2006 Aug 14;12(30):4927-9
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatitis complicating mucin-hypersecreting common bile duct adenoma.
  • Villous adenomas of the bile ducts are extremely uncommon.
  • Preoperative investigation demonstrated a dilated papillary orifice with mucus exiting (fish-mouth sign) and a filling defect in the distal common bile duct.
  • He underwent a modified Whipple operation and histological examination of the surgical specimen showed villous adenoma with rich secretion of mucus.
  • [MeSH-major] Adenoma, Bile Duct / complications. Bile Duct Neoplasms / complications. Bile Ducts, Intrahepatic / pathology. Mucins / secretion. Pancreatitis / etiology

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 1990 May;31(5):558-60 [2190867.001]
  • [Cites] AJR Am J Roentgenol. 1990 Jun;154(6):1217-8 [2110730.001]
  • [Cites] Abdom Imaging. 1993;18(3):245-6 [8508085.001]
  • [Cites] J R Soc Med. 1993 Oct;86(10):603-4 [8230068.001]
  • [Cites] Gastroenterol Clin Biol. 1995 Oct;19(10):850-1 [8566571.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1909-18 [8964418.001]
  • [Cites] J Clin Gastroenterol. 1996 Jan;22(1):77-9 [8776106.001]
  • [Cites] Hum Pathol. 1997 Sep;28(9):1010-7 [9308724.001]
  • [Cites] Dtsch Med Wochenschr. 1997 Oct 10;122(41):1248-52 [9378054.001]
  • [Cites] Yonsei Med J. 1999 Feb;40(1):84-9 [10198612.001]
  • [Cites] Isr Med Assoc J. 2002 Dec;4(12):1149-50 [12516913.001]
  • [Cites] Gastrointest Endosc. 2003 Apr;57(4):561-2 [12665769.001]
  • [Cites] Gut. 1983 Apr;24(4):333-9 [6832628.001]
  • [Cites] Dis Colon Rectum. 1983 Aug;26(8):525-8 [6872780.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):65-72 [6327000.001]
  • [Cites] Gut. 1987 Oct;28(10):1320-1 [3678961.001]
  • [Cites] Arch Surg. 1988 Jan;123(1):96 [3337662.001]
  • [Cites] Gastrointest Endosc. 1992 Jul-Aug;38(4):504-6 [1511829.001]
  • (PMID = 16937485.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mucins
  • [Other-IDs] NLM/ PMC4087637
  •  go-up   go-down


26. Wang L, Camus AC, Dong W, Thornton C, Willett KL: Expression of CYP1C1 and CYP1A in Fundulus heteroclitus during PAH-induced carcinogenesis. Aquat Toxicol; 2010 Sep 15;99(4):439-47
Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathologic findings included foci of cellular alteration and neoplasms, including hepatocellular adenoma, hepatocellular carcinoma and cholangioma.
  • In contrast, CYP1C1 was only detectable and highly expressed in proliferated bile duct epithelial cells.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Benzo(a)pyrene .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier B.V. All rights reserved.
  • [Cites] Mol Pharmacol. 1993 Feb;43(2):200-6 [8381508.001]
  • [Cites] Carcinogenesis. 1994 Apr;15(4):565-72 [8149464.001]
  • [Cites] J Biol Chem. 1994 May 27;269(21):14905-11 [8195121.001]
  • [Cites] Carcinogenesis. 1995 Sep;16(9):2029-36 [7554050.001]
  • [Cites] Environ Health Perspect. 1996 Mar;104 Suppl 1:5-21 [8722107.001]
  • [Cites] Toxicol Pathol. 1996 Sep-Oct;24(5):603-18 [8923683.001]
  • [Cites] Toxicol Appl Pharmacol. 1997 Feb;142(2):348-59 [9070358.001]
  • [Cites] Toxicol Pathol. 1997 Mar-Apr;25(2):202-10 [9125779.001]
  • [Cites] Mutat Res. 1998 Mar 20;399(2):193-219 [9672660.001]
  • [Cites] EXS. 1998;86:141-64 [9949876.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Nov 15;201(1):40-52 [15519607.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 17;331(4):1016-24 [15882979.001]
  • [Cites] Environ Sci. 2005;12(2):111-20 [15915151.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5978-86 [2168287.001]
  • [Cites] Carcinogenesis. 1992 Mar;13(3):505-7 [1547543.001]
  • [Cites] Toxicol Appl Pharmacol. 1992 Apr;113(2):319-24 [1561641.001]
  • [Cites] Endocrinology. 1992 Dec;131(6):3067-76 [1332854.001]
  • [Cites] J Biol Chem. 2000 Mar 10;275(10):6770-6 [10702233.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2273-80 [10786695.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:297-316 [11264459.001]
  • [Cites] Drug Metab Dispos. 2001 Sep;29(9):1176-82 [11502724.001]
  • [Cites] Semin Liver Dis. 2002 Aug;22(3):241-9 [12360418.001]
  • [Cites] Toxicol Sci. 2003 Jan;71(1):20-6 [12520072.001]
  • [Cites] Cancer Sci. 2004 Jan;95(1):1-6 [14720319.001]
  • [Cites] Toxicol Pathol. 2004 Jul-Aug;32(4):375-83 [15307209.001]
  • [Cites] Cancer Res. 1982 Dec;42(12):4875-917 [6814745.001]
  • [Cites] Natl Cancer Inst Monogr. 1984 May;65:321-36 [6087143.001]
  • [Cites] Anat Rec. 1985 Oct;213(2):166-75 [3000224.001]
  • [Cites] Anat Rec. 1988 Jun;221(2):619-34 [2970812.001]
  • [Cites] DNA. 1988 Jul-Aug;7(6):379-87 [3203599.001]
  • [Cites] Ecotoxicol Environ Saf. 1988 Dec;16(3):219-31 [2852591.001]
  • [Cites] Cancer Res. 1990 Jul 1;50(13):3811-5 [1693878.001]
  • [Cites] Sci Total Environ. 1990 May 1;94(1-2):155-67 [2163106.001]
  • [Cites] Aquat Toxicol. 2006 May 10;77(3):267-78 [16458981.001]
  • [Cites] World J Gastroenterol. 2006 Jun 14;12(22):3553-63 [16773712.001]
  • [Cites] Toxicol Sci. 2006 Oct;93(2):331-40 [16873418.001]
  • [Cites] Dis Aquat Organ. 2006 Sep 14;72(1):19-30 [17067070.001]
  • [Cites] Mol Biol Cell. 2007 Apr;18(4):1472-9 [17314404.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 May 15;221(1):29-41 [17445853.001]
  • [Cites] Mar Pollut Bull. 2007 Sep;54(9):1529-39 [17624373.001]
  • [Cites] Toxicol Sci. 2007 Nov;100(1):180-93 [17686920.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Feb 15;863(1):141-9 [18255360.001]
  • [Cites] Arch Biochem Biophys. 2009 Feb;482(1-2):7-16 [19103147.001]
  • [Cites] Aquat Toxicol. 2009 May 5;92(3):195-201 [19269699.001]
  • [Cites] Aquat Toxicol. 2009 Jul 26;93(4):234-43 [19515436.001]
  • [Cites] Aquat Toxicol. 2010 Aug 1;99(1):33-41 [20471113.001]
  • [Cites] Arch Biochem Biophys. 2010 Oct 1;502(1):17-22 [20599672.001]
  • [Cites] Environ Health Perspect. 2010 Oct;118(10):1376-81 [20501349.001]
  • (PMID = 20621368.001).
  • [ISSN] 1879-1514
  • [Journal-full-title] Aquatic toxicology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Aquat. Toxicol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES012710-05S1; United States / NIEHS NIH HHS / ES / R01 ES012710; United States / NIEHS NIH HHS / ES / R01 ES012710-05S1; United States / NIEHS NIH HHS / ES / R01ES012710
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 3417WMA06D / Benzo(a)pyrene; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; YOW8V9698H / Dimethyl Sulfoxide
  • [Other-IDs] NLM/ NIHMS222714; NLM/ PMC2924930
  •  go-up   go-down


27. Xu HX, Chen LD: Villous adenoma of extrahepatic bile duct: contrast-enhanced sonography findings. J Clin Ultrasound; 2008 Jan;36(1):39-41
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villous adenoma of extrahepatic bile duct: contrast-enhanced sonography findings.
  • We report a case of villous adenoma in the extrahepatic bile duct that was successfully diagnosed with contrast-enhanced sonography (CEUS) before surgical resection.
  • On baseline sonography, the mass appeared as a homogeneously isoechoic mass filling the bile duct from the confluence of the right and left hepatic ducts to the distal common bile duct.
  • Surgical resection was performed, and pathologic examination confirmed a villous adenoma of the bile duct epithelium with mild dysplasia.
  • [MeSH-major] Adenoma, Villous / ultrasonography. Bile Duct Neoplasms / ultrasonography. Bile Ducts, Extrahepatic / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley Periodicals, Inc.
  • (PMID = 17565756.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


28. Fischer HP, Zhou H: [Nodular lesions of liver parenchyma caused by pathological vascularisation/perfusion]. Pathologe; 2006 Jul;27(4):273-83
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast to hepatocellular adenoma, they show a more or less nodular architecture with fibrous septa and ductular structures.
  • NRH and cases of MRN without cirrhosis can indicate an extrahepatic/systemic disease causing altered liver perfusion.
  • Telangiectatic FNH might resemble classic hepatocellular adenoma.
  • Neoductular transformation of hypoperfused liver parenchyma might imitate cholangioma or cholangiocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16773311.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 45
  •  go-up   go-down


29. Xie CM, Zheng L, Mo YX, Li L, Ruan CM, Lu YC, Wu PH: [Helical double-phase CT scan imaging features of hepatocellular carcinoma and pathology of false-positive lesions]. Ai Zheng; 2007 Jan;26(1):68-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: CT scan showed 56 lesions in the 52 patients: 51 were cancer lesions, including 49 HCC lesions and 2 mixed lesions of HCC and cholangioma, 5 were false-positive lesions.
  • The pathologic diagnoses of the 5 false-positive lesions were hepatic cirrhosis with hepatocellular nodular hyperplasia, regenerative nodule, hepatic cirrhosis, bile duct calculus companied with inflammatory reaction, and fibrosis hyperplasia.

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222371.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. National Toxicology Program: Toxicology and carcinogenesis studies of a binary mixture of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (Cas No. 57465-28-8) and 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) (CAS No. 35065-27-1) in female Harlan Sprague-Dawley rats (gavage studies). Natl Toxicol Program Tech Rep Ser; 2006 Aug;(530):1-258
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicology and carcinogenesis studies of a binary mixture of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (Cas No. 57465-28-8) and 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) (CAS No. 35065-27-1) in female Harlan Sprague-Dawley rats (gavage studies).
  • Since human exposure to DLCs always occurs as a complex mixture, the toxic equivalency factor (TEF) methodology has been developed as a mathematical tool to assess the health risk posed by complex mixtures of these compounds.
  • The TEF methodology is a relative potency scheme that ranks the dioxin-like activity of a compound relative to TCDD, the most potent congener.
  • This allows for the estimation of the potential dioxin-like activity of a mixture of chemicals, based on a common mechanism of action involving an initial binding of DLCs to the AhR.
  • 2-YEAR STUDY: The 2-year study of a binary mixture of PCB 126 and PCB 153 was designed to assess the carcinogenicity of a constant ratio mixture of PCB 126 and PCB 153.
  • At the end of the 2-year study, there were significantly increased incidences and severities of toxic hepatopathy characterized by hepatocyte hypertrophy, multinucleated hepatocytes, pigmentation, diffuse and focal fatty change, eosinophilic focus, nodular hyperplasia, cholangiofibrosis, oval cell hyperplasia, bile duct cysts, bile duct hyperplasia, necrosis, and portal fibrosis.
  • Significantly increased incidences of hepatocellular adenoma, cholangiocarcinoma, and hepatocholangioma were observed in the study.

  • Hazardous Substances Data Bank. 2,2',4,4',5,5'-HEXACHLOROBIPHENYL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160104.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; DFC2HB4I0K / Polychlorinated Biphenyls; TSH69IA9XF / 3,4,5,3',4'-pentachlorobiphenyl; ZRU0C9E32O / 2,4,5,2',4',5'-hexachlorobiphenyl
  •  go-up   go-down


31. National Toxicology Program: NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies). Natl Toxicol Program Tech Rep Ser; 2006 Jan;(520):4-246

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since human exposure to DLCs always occurs as a complex mixture, the Toxic Equivalency Factor (TEF) methodology has been developed as a mathematical tool to assess the health risk posed by complex mixtures of these compounds.
  • The TEF methodology is a relative potency scheme that ranks the dioxin-like activity of a compound relative to TCDD that is the most potent congener.
  • This allows for the estimation of the potential dioxin-like activity of a mixture of chemicals, based on a common mechanism of action involving an initial binding of DLCs to the AhR.
  • 3,3',4,4',5-Pentachlorobiphenyl (PCB 126) was produced commercially before 1977 for the electric industry as a dielectric insulating fluid for transformers and capacitors.
  • PCB 126 was selected for study by the National Toxicology Program as a part of the dioxin TEF evaluation to assess the cancer risk posed by complex mixtures of polychlorinated dibenzodioxins (PCDDs), polychlorinated dibenzofurans (PCDFs), and PCBs.
  • At 2 years, there were significant treatment-related increases in the incidences of cholangiocarcinoma and hepatocellular adenoma.
  • Three hepatocholangiomas were seen in the 1,000 ng/kg core study group and a single incidence of cholangioma each occurred in the 550 and 1,000 ng/kg core study groups.
  • At 2 years, a significant dose-related increase in hepatic toxicity was observed and was characterized by increased incidences of numerous lesions including hepatocyte hypertrophy, multinucleated hepatocytes, diffuse fatty change, bile duct hyperplasia, bile duct cyst, oval cell hyperplasia, necrosis, pigmentation, inflammation, nodular hyperplasia, portal fibrosis, cholangiofibrosis, and toxic hepatopathy.
  • At 2 years, adenomas and/or carcinomas were present in the adrenal cortex of most core study groups and in the 1,000 ng/kg stop-exposure group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628245.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Thyroid Hormones; DFC2HB4I0K / Polychlorinated Biphenyls; TSH69IA9XF / 3,4,5,3',4'-pentachlorobiphenyl
  •  go-up   go-down


32. Nassar H, Albores-Saavedra J, Klimstra DS: High-grade neuroendocrine carcinoma of the ampulla of vater: a clinicopathologic and immunohistochemical analysis of 14 cases. Am J Surg Pathol; 2005 May;29(5):588-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overall, 64% of patients with ampullary HGNEC died of disease (mean follow-up, 14.5 months).
  • Four patients had no evidence of disease after resection (mean, 20 months).
  • Half of the tumors were associated with adenomas of the adjacent mucosa, 2 with high-grade dysplasia.
  • The association with adenoma and or conventional adenocarcinoma components may suggest a common pathway in the initial carcinogenesis of these two types of tumors.
  • Loss of Rb expression, a characteristic finding in pulmonary SCCs, is present in almost half of ampullary HGNECs.
  • [MeSH-major] Ampulla of Vater / pathology. Carcinoma, Neuroendocrine / pathology. Common Bile Duct Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832081.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


33. National Toxicology Program: NTP technical report on the toxicology and carcinogenesis studies of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS No. 1746-01-6) in female Harlan Sprague-Dawley rats (Gavage Studies). Natl Toxicol Program Tech Rep Ser; 2006 Apr;(521):4-232
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since human exposure to DLCs always involves a complex mixture, the toxic equivalency factor (TEF) methodology has been developed as a mathematical tool to assess the health risk posed by complex mixtures of these compounds.
  • The TEF methodology is a relative potency scheme that ranks the dioxin-like activity of a compound relative to TCDD, which is the most potent congener.
  • This allows for the estimation of the potential dioxin-like activity of a mixture of chemicals based on a common mechanism of action involving an initial binding of DLCs to the AhR.
  • TCDD (dioxin) was selected for study by the National Toxicology Program as a part of the dioxin TEF evaluation to assess the cancer risk posed by complex mixtures of polychlorinated dibenzodioxins (PCDDs), polychlorinated dibenzofurans (PCDFs), and PCBs.
  • At 2 years, there was a significant increase in toxic hepatopathy characterized by increased incidences of numerous nonneoplastic liver lesions including hepatocyte hypertrophy, multinucleated hepatocytes, altered hepatocellular foci, inflammation, pigmentation, diffuse fatty change, necrosis, portal fibrosis, oval cell hyperplasia, bile duct hyperplasia, bile duct cysts, cholangiofibrosis, and nodular hyperplasia At 2 years, the incidence of hepatocellular adenoma was significantly increased in the 100 ng/kg core study group.
  • Two cholangiocarcinomas and two hepatocellular adenomas were seen in the 100 ng/kg stop-exposure group.
  • Two hepatocholangiomas were seen in the 100 ng/kg core study group, and one cholangioma was seen in the 100 ng/kg stop-exposure group.
  • At 2 years, one acinar adenoma and two acinar cell carcinomas of the pancreas were seen in the 100 ng/kg core study group; one acinar carcinoma was seen in the 100 ng/kg stop-exposure group.
  • The incidences of acinar cell adenoma or carcinoma (combined) exceeded the historical vehicle control range.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835633.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; DO80M48B6O / Tetrachlorodibenzodioxin
  •  go-up   go-down


34. National Toxicology Program: NTP carcinogenesis studies of 2,2-bis(bromomethyl)-1,3-propanediol, nitromethane, and 1,2,3-trichloropropane (cas nos. 3296-90-0, 75-52-5, and 96-18-4) in guppies (Poecilia reticulata) and medaka (Oryzias latipes) (Waterborne Studies). Natl Toxicol Program Tech Rep Ser; 2005 Oct;(528):1-190
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of small fish species in carcinogenicity testing offered potential advantages as a bioassay test system, including significant savings in cost and time over rodent studies.
  • At 9 months, hepatocellular adenomas occurred in one 24 mg/L male and in one 150 mg/L male.
  • In the core study, the incidence of hepatocellular adenoma or carcinoma (combined) in 150 mg/L males was greater than that in the controls; multiple adenomas occurred in two 150 mg/L males and in one 150 mg/L female.
  • Cholangioma occurred in a small number of exposed males and females.
  • In the stop-exposure study, incidences of hepatocellular adenoma (including multiple) and of hepatocellular carcinoma were greater in 150 mg/L males than in controls.
  • One cholangioma and one cholangiocarcinoma occurred in the 150 mg/L female group.
  • In the core study, the incidence of hepatocellular adenoma or carcinoma (combined) was increased in 150 mg/L males.
  • One cholangioma occurred in a 150 mg/L female, and one occurred in a control female.
  • In the stop-exposure study, incidences of hepatocellular adenoma or carcinoma (combined) were marginally increased in the 150 mg/L group of males and in the 60 and 150 mg/L groups of females as compared with controls.
  • The biological significance of this finding is unknown.
  • Hepatocellular adenomas occurred in two 20 mg/L males and in one 40 mg/L female.
  • In the core study, one cholangioma occurred in a 20 mg/L male, and cholangiocarcinomas were seen in a few exposed males, but none occurred in control males.
  • At 9 months, multiple hepatocellular adenomas occurred in one 4.5 mg/L male, and one hepatocellular adenoma occurred in a control male.
  • In the core study, increased incidences of cholangiocellular (bile duct) and hepatocellular neoplasms occurred in exposed groups of males and females.
  • Cholangioma and cholangiocarcinoma were seen in several exposed males and females.
  • In the stop-exposure study, increased incidences of hepatocellular neoplasms occurred in 18.0 mg/L males and increased incidences of cholangiocellular (bile duct) neoplasms occurred in 18.0 mg/L females. (ABSTRACT TRUNCATED)

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. 2,2-Bis(bromomethyl)-1,3-propanediol .
  • Hazardous Substances Data Bank. METHANE .
  • Hazardous Substances Data Bank. PROPANE .
  • Hazardous Substances Data Bank. NITROMETHANE .
  • Hazardous Substances Data Bank. 1,2,3-TRICHLOROPROPANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16362062.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Nitroparaffins; 0 / Propylene Glycols; 0 / Water Pollutants, Chemical; 3296-90-0 / 2,2-bis(bromomethyl)-1,3-propanediol; 3MJ7QCK0Z0 / 1,2,3-trichloropropane; OP0UW79H66 / Methane; RU5WG8C3F4 / nitromethane; T75W9911L6 / Propane
  •  go-up   go-down


35. National Toxicology Program: Toxicology and carcinogenesis studies of a binary mixture of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (Cas No. 57465-28-8) and 2,3',4,4',5-pentachlorobiphenyl (PCB 118) (Cas No. 31508-00-6) in female Harlan Sprague-Dawley rats (gavage studies). Natl Toxicol Program Tech Rep Ser; 2006 Nov;(531):1-218

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicology and carcinogenesis studies of a binary mixture of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (Cas No. 57465-28-8) and 2,3',4,4',5-pentachlorobiphenyl (PCB 118) (Cas No. 31508-00-6) in female Harlan Sprague-Dawley rats (gavage studies).
  • Since human exposure to DLCs always occurs as a complex mixture, the toxic equivalency factor (TEF) methodology has been developed as a mathematical tool to assess the health risk posed by complex mixtures of these compounds.
  • The TEF methodology is a relative potency scheme that ranks the dioxin-like activity of a compound relative to TCDD, which is the most potent congener.
  • This allows for the estimation of the potential dioxin-like activity of a mixture of chemicals, based on a common mechanism of action involving an initial binding of DLCs to the AhR.
  • Therefore, this study was reclassified as a mixture study of PCB 126 and PCB 118.
  • At the end of the 2-year study in all dosed groups, there were significantly increased incidences and severity of toxic hepatopathy characterized by hepatocyte hypertrophy, multinucleated hepatocytes, pigmentation, toxic hepatopathy, diffuse fatty change, nodular hyperplasia, centrilobular fibrosis, cholangiofibrosis, oval cell hyperplasia, bile duct cyst, bile duct hyperplasia, and portal fibrosis.
  • The incidences of hepatocellular adenoma were also significantly increased in the 216 and 360 ng TEQ/kg core study groups.
  • In addition, single occurrences of hepatocholangioma, cholangioma, or hepatocellular carcinoma were observed in some dosed groups administered 72 ng TEQ/kg or greater.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17342196.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thyroid Hormones; 31508-00-6 / 2,3',4,4',5-pentachlorobiphenyl; DFC2HB4I0K / Polychlorinated Biphenyls; TSH69IA9XF / 3,4,5,3',4'-pentachlorobiphenyl
  •  go-up   go-down


36. National Toxicology Program: Toxicology and carcinogenesis studies of 2,3',4,4',5-pentachlorobiphenyl (PCB 118) (CAS No. 31508-00-6) in female harlan Sprague-Dawley rats (gavage studies). Natl Toxicol Program Tech Rep Ser; 2010 Nov;(559):1-174

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since human exposure to DLCs always occurs as a complex mixture, the toxic equivalency factor (TEF) methodology has been developed as a mathematical tool to assess the health risk posed by complex mixtures of these compounds.
  • The TEF methodology is a relative potency scheme that ranks the dioxin-like activity of a compound relative to TCDD, which is the most potent congener.
  • This allows for the estimation of the potential dioxin-like activity of a mixture of chemicals, based on a common mechanism of action involving an initial binding of DLCs to the AhR.
  • At the 53-week interim evaluation, three 4,600 g/kg rats had liver cholangiocarcinoma and one had hepatocellular adenoma.
  • At 2 years, there were significant treatment-related increases in the incidences of cholangiocarcinoma and hepatocellular adenoma.
  • Four incidences of hepatocholangioma occurred in the 4,600 g/kg core study group.
  • At 2 years, a significant dose-related increase in hepatic toxicity was observed and was characterized by increased incidences of numerous lesions including hepatocyte hypertrophy, inflammation, oval cell hyperplasia, pigmentation, multinucleated hepatocyte, eosinophilic and mixed cell foci, diffuse fatty change, toxic hepatopathy, nodular hyperplasia, necrosis, bile duct hyperplasia and cyst, and cholangiofibrosis.
  • At 2 years, there were marginally increased incidences of exocrine pancreatic adenoma or carcinoma in the 460, 1,000, and 4,600 g/kg core study groups.
  • CONCLUSIONS: Under the conditions of this 2-year gavage study, there was clear evidence of carcinogenic activity of PCB 118 in female Harlan Sprague-Dawley rats based on increased incidences of neoplasms of the liver (cholangiocarcinoma, hepatocholangioma, and hepatocellular adenoma) and cystic keratinizing epithelioma of the lung.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21383778.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 31508-00-6 / 2,3',4,4',5-pentachlorobiphenyl; DFC2HB4I0K / Polychlorinated Biphenyls; DO80M48B6O / Tetrachlorodibenzodioxin
  •  go-up   go-down


37. Arena V, Arena E, Stigliano E, Capelli A: Bile duct adenoma with oncocytic features. Histopathology; 2006 Sep;49(3):318-20
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bile duct adenoma with oncocytic features.
  • [MeSH-major] Adenoma, Bile Duct / pathology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Oxyphil Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918984.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


38. Otani K, Tohara K, Mihara K, Ueki T, Tanaka M, Sakaguchi S, Matsui T, Yao T, Haraoka S, Iwashita A: [A case of intrahepatic bile duct adenoma]. Nihon Shokakibyo Gakkai Zasshi; 2006 Jan;103(1):37-43
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of intrahepatic bile duct adenoma].
  • [MeSH-major] Adenoma, Bile Duct / diagnosis. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444984.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement